Megan Clark Purchases 200 Shares of CSL Limited (ASX:CSL) Stock

CSL Limited (ASX:CSL) insider Megan Clark purchased 200 shares of the stock in a transaction on Monday, March 17th. The stock was acquired at an average price of A$250.06 ($159.27) per share, for a total transaction of A$50,012.00 ($31,854.78).

Megan Clark also recently made the following trade(s):

• On Wednesday, February 19th, Megan Clark acquired 132 shares of CSL stock. The stock was purchased at an average cost of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).

CSL Price Performance

The stock has a market cap of $77.43 billion, a P/E ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a quick ratio of 1.68 and a current ratio of 1.86.

CSL Increases Dividend

The company also recently disclosed a Interim dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Tuesday, April 8th will be given a $2.073 dividend. This represents a dividend yield of 0.81%. The ex-dividend date of this dividend is Sunday, March 9th. This is an increase from CSL’s previous Interim dividend of $1.83. CSL’s dividend payout ratio (DPR) is 50.38%.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.